Profile
Sector:
HealthcareCountry:
United StatesIPO:
29 December 2014Website:
http://www.indivior.comNext earnings report:
N/ALast dividends:
16 June 2016Next dividends:
N/APrice
after hours | 44 min agoDividend
Analysts recommendations
Institutional Ownership
INDV Latest News
NEW YORK, NY / ACCESSWIRE / September 28, 2024 / If you suffered a loss on your Indivior PLC (NASDAQ:INDV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/indivior-lawsuit-submission-form?prid=105806&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / September 25, 2024 / If you suffered a loss on your Indivior PLC (NASDAQ:INDV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/indivior-lawsuit-submission-form?prid=105014&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK , Sept. 23, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Indivior PLC (NASDAQ: INDV).
NEW YORK, NY / ACCESSWIRE / September 16, 2024 / If you suffered a loss on your Indivior PLC (NASDAQ:INDV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/indivior-lawsuit-submission-form?prid=102884&wire=1 or contact Joseph E. Levi, Esq.
SAN DIEGO, Sept. 13, 2024 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed on behalf of purchasers or acquirers of Indivior PLC (NASDAQ: INDV) (“Indivior” or the “Company”) securities between February 22, 2024 and July 8, 2024, inclusive (the “Class Period”), charging the Company and certain senior executives with violations of the federal securities laws (collectively, “Defendants”).
NEW YORK, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Indivior PLC ("Indivior" or the "Company") (NASDAQ: INDV) of a class action securities lawsuit.
NEW YORK, NY / ACCESSWIRE / August 31, 2024 / If you suffered a loss on your Indivior PLC (NASDAQ:INDV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/indivior-lawsuit-submission-form?prid=99436&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / August 21, 2024 / If you suffered a loss on your Indivior PLC (NASDAQ:INDV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/indivior-lawsuit-submission-form?prid=97288&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / August 21, 2024 / If you suffered a loss on your Indivior PLC (NASDAQ:INDV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/indivior-lawsuit-submission-form?prid=97211&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / August 20, 2024 / If you suffered a loss on your Indivior PLC (NASDAQ:INDV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/indivior-lawsuit-submission-form?prid=96929&wire=1 or contact Joseph E. Levi, Esq.
- 1(current)
- 2
What type of business is Indivior?
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
What sector is Indivior in?
Indivior is in the Healthcare sector
What industry is Indivior in?
Indivior is in the Drug Manufacturers - Specialty & Generic industry
What country is Indivior from?
Indivior is headquartered in United States
When did Indivior go public?
Indivior initial public offering (IPO) was on 29 December 2014
What is Indivior website?
https://www.indivior.com
Is Indivior in the S&P 500?
No, Indivior is not included in the S&P 500 index
Is Indivior in the NASDAQ 100?
No, Indivior is not included in the NASDAQ 100 index
Is Indivior in the Dow Jones?
No, Indivior is not included in the Dow Jones index
When was Indivior the previous earnings report?
No data
When does Indivior earnings report?
Next earnings report date is not announced yet